Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Cash & Equivalents (2020 - 2025)

Biofrontera (BFRI) has 6 years of Cash & Equivalents data on record, last reported at $3.4 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 17.83% year-over-year to $3.4 million; the TTM value through Sep 2025 reached $3.4 million, up 17.83%, while the annual FY2024 figure was $5.9 million, 339.69% up from the prior year.
  • Cash & Equivalents reached $3.4 million in Q3 2025 per BFRI's latest filing, down from $7.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $31.9 million in Q2 2022 and bottomed at $1.3 million in Q1 2023.
  • Average Cash & Equivalents over 5 years is $10.0 million, with a median of $4.1 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: surged 1502.56% in 2022, then plummeted 94.2% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $24.5 million in 2021, then fell by 29.76% to $17.2 million in 2022, then crashed by 92.2% to $1.3 million in 2023, then surged by 339.69% to $5.9 million in 2024, then tumbled by 42.13% to $3.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $3.4 million in Q3 2025, $7.2 million in Q2 2025, and $1.8 million in Q1 2025.